BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24198241)

  • 21. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer.
    Wei F; Liu Y; Guo Y; Xiang A; Wang G; Xue X; Lu Z
    Mol Cancer; 2013 Jul; 12():81. PubMed ID: 23886294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mtor inhibition by INK128 extends functions of the ovary reconstituted from germline stem cells in aging and premature aging mice.
    Heng D; Sheng X; Tian C; Li J; Liu L; Gou M; Liu L
    Aging Cell; 2021 Feb; 20(2):e13304. PubMed ID: 33448083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
    Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
    Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity.
    Rath BH; Waung I; Camphausen K; Tofilon PJ
    Mol Cancer Ther; 2018 May; 17(5):1070-1078. PubMed ID: 29483212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
    Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
    Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
    Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
    Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway.
    Tan B; Huang Y; Zhang B; Lin N
    Biomed Pharmacother; 2020 Aug; 128():110133. PubMed ID: 32447207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
    Janes MR; Vu C; Mallya S; Shieh MP; Limon JJ; Li LS; Jessen KA; Martin MB; Ren P; Lilly MB; Sender LS; Liu Y; Rommel C; Fruman DA
    Leukemia; 2013 Mar; 27(3):586-94. PubMed ID: 23090679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
    Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
    Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmented pentose phosphate pathway plays critical roles in colorectal carcinomas.
    Shibuya N; Inoue K; Tanaka G; Akimoto K; Kubota K
    Oncology; 2015; 88(5):309-19. PubMed ID: 25591719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endoplasmic reticulum stress sensitizes human esophageal cancer cell to radiation.
    Pang XL; He G; Liu YB; Wang Y; Zhang B
    World J Gastroenterol; 2013 Mar; 19(11):1736-48. PubMed ID: 23555162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma.
    Tsai CL; Hsu FM; Tzen KY; Liu WL; Cheng AL; Cheng JC
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1317-24. PubMed ID: 25682950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
    Mitchell JB; Choudhuri R; Fabre K; Sowers AL; Citrin D; Zabludoff SD; Cook JA
    Clin Cancer Res; 2010 Apr; 16(7):2076-84. PubMed ID: 20233881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.
    Eke I; Makinde AY; Aryankalayil MJ; Sandfort V; Palayoor ST; Rath BH; Liotta L; Pierobon M; Petricoin EF; Brown MF; Stommel JM; Ahmed MM; Coleman CN
    Mol Cancer Ther; 2018 Feb; 17(2):355-367. PubMed ID: 28802252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
    Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
    Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
    Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH
    Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
    Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Aug; 61(8):1486-9. PubMed ID: 24623675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.